No takes yet. Share an insight, caveat, or question.
Clinical trial demonstrates azacitidine plus LDAC improves overall response rate in frail elderly AML patients, suggesting a promising treatment option.
Guo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: